Detail akcie Bioline RX RSp ADR online

Business Summary: BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Financial Summary: BRIEF: For the six months ended 30 June 2025, BioLine RX Ltd - ADR revenues decreased 95% to $559K. Net income totaled $1.2M vs. loss of $212K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net Income reflects Sales and marketing expenses decrease from $12.8M (expense) to $0K, Financial Expenses decrease of 77% to $696K (expense).